{"prompt": "['Alliance A171601', '93', 'MJ P, MC M, HJ C: Allostatic load of circulating biomarkers on gait speed in cancer survivors.', 'Bethesda, MD, 2012', '94', 'McMillan DC: The systemic inflammation-based Glasgow Prognostic Score: a decade of', 'experience in patients with cancer. Cancer Treat Rev 39:534-40, 2013', '95.', 'Sharma R, Zucknick M, London R, et al: Systemic inflammatory response predicts prognosis in', 'patients with advanced-stage colorectal cancer. Clin Colorectal Cancer 7:331-7, 2008', '96.', 'Campisi J: Senescent cells, tumor suppression, and organismal aging: good citizens, bad', 'neighbors. Cell 120:513-22, 2005', '97.', 'Coppe JP, Patil CK, Rodier F, et al: Senescence-associated secretory phenotypes reveal cell-', 'nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS biology', '6:2853-68, 2008', '98', 'Dowsett M, Cuzick J, Ingle J, Coates A, et al: Meta-analysis of breast cancer outcomes in', 'adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010; 28(3):509-', '518.10.1200/JCO.2009.23.1274 [PubMed: 19949017]', '99', 'Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, et al : Exemestane for', 'breast-cancerprevention in postmenopausal women. N Engl J Med. 2011; 364(25):2381-', '2391.10.1056/NEJMoal103507 [PubMed: 21639806]', '100', 'Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, et al: A randomized trial of letrozole in', 'postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N', 'Engl J Med. 2003; 349(19):1793-1802. [PubMed: 14551341]', '101', 'Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in', 'postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst.', '2011;103(17):1299-1309.10.1093/jnci/djr242| [PubMed: 21743022]', '102', 'Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, et al :Prospective', 'characterization of musculoskeletal symptoms in early stage breast cancer patients treated with', 'aromatase inhibitors. Breast Cancer Res Treat. 2008; 111(2):365-372. [PubMed: 17922185]', '103', 'Bartsch R, Bergen E. ASCO 2016: highlights in breast cancer. Memo.2016;9(4):211-214.', '10.1007/s12254-016-0300-6. Review. PubMed PMID: 28058064;PubMed Central PMCID:', 'PMC5165027', '104', 'Poggio F, Lambertini M, Blondeaux E, Vaglica M, Levaggi A, et al: Role of fulvestrant in the', 'treatment of postmenopausal metastatic breast cancer patients. Expert Rev Clin Pharmacol 2016', 'Sep;9(9):1153-61. doi:10.1080/17512433.2016.1215243. PubMed PMID: 27545815.', '105', 'Finn RS, Crown JP, Lang I, et al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in', 'combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-', 'positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2', 'study. Lancet Oncology 16:25-35, 2015.', '106', 'Turner NC, Ro J, Andr\u00e9l F, Lois, Verma S, et al: PALOMA3 Study Group. Palbociclib in', 'Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jul 16;373(3):209-19', 'doi: 10.1056/NEJMoal505270. PubMed PMID:26030518.', '107', 'Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, et al: Fulvestrant plus palbociclib versus', 'fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic', 'breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the', 'multicentre, double-blind, phase 3 randomised controlled trial.Lancet Oncol. 2016', 'Apr;17(4):425-39. doi: 10.1016/S1470-2045(15)00613-0 PubMed PMID: 26947331.', '108', 'Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor,', 'preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell', 'lines in vitro. Breast Cancer Research : BCR. 2009;11(5):R77. doi:10.1186/bcr2419', '82', 'NCIVersion Date: 5/29/2020', 'Update 5']['Alliance A171601', '109', 'Pfizer Inc. IbranceR (palbociclib): HIGHLIGHTS OF PRESCRIBING INFORMATION,', 'Revised: 2/2016. https://www.pfizermedicalinformation.com/en-us/ibrance:HIGHLIGHTS OF', 'PRESCRIBING INFORMATION, Revised: 2/2016.', '110', 'Mangini NS, WesolowskiR, Ramaswamy B, Lustberg MB, Berger MJ. Palbociclib: A Novel', 'Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.', 'Ann Pharmacother 2015 Nov;49(11):1252-60. doi:10.1177/1060028015602273.Review.', 'PubMed PMID: 26324355', '111', 'Roberts PJ, Bisi JE, Strum JC, et al. Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in', 'Cancer Therapy. JNCI Journal of the National Cancer Institute. 2012;104(6):476-487.', 'doi:10.1093/jmci/djo02.', '112', 'McClendon AK, Dean JL, Rivadeneira DB, et al. CDK4/6 inhibition antagonizes the cytotoxic', 'response to anthracycline therapy. Cell Cycle. 2012;11(14):2747-2755. doi:10.4161/cc.21127.', '113', 'Verma S, Bartlett CH, Schnell P, DeMichele AM, Loi S, Ro J, Colleoni M, et al:. Palbociclib in', 'Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative', 'Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized,', 'Placebo-Controlled, Phase III Study (PALOMA-3). Oncologist. 2016 Oct;21(10):1165-1175.', 'PubMed PMID: 27368881; PubMed Central PMCID: PMC5061543.', '114', 'Henry NL, Skaar TC, Dantzer J, LiL, Kidwell K, et al: Genetic associations with toxicity-related', 'discontinuation of aromatase inhibitor therapy for breast cancer. Breast Cancer Res Treat. 2013', 'Apr;138(3):807-16. doi: 10.1007/s10549-013-2504 3. PubMed PMID: 23546553; PubMed', 'Central PMCID: PMC3646626.', '115', 'Colomer R, Monzo M, Tusquets I, Rifa J, et al: A single-nucleotide polymorphism in the', 'aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced', 'breast carcinoma. Clin Cancer Res. 2008; 14(3):811-816.10.1158/1078-0432.CCR-07-1923', '[PubMed: 18245543]', '116', 'Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, et al: Genome-wide associations and', 'functional genomic studies of musculoskeletal adverse events in women receiving aromatase', 'inhibitors. JClin Oncol. 2010; ;28(31):4674-4682.10.1200/JCO.2010.28.5064 [PubMed:', '20876420]', '117', 'Mao JJ, Sul HI, Feng R, Donelson ML, et al: Association of functional polymorphisms in', 'CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer', 'Res. 2011; 13(1):R8.10.1186/bcr2813 [PubMed: 21251330]', '118', 'Park IH, Lee YS, Lee KS, Kim SY, et al :. Single nucleotide polymorphisms of CYP19A1 predict', 'clinical outcomes and adverse events associated with letrozole in patients with metastatic breast', 'cancer. Cancer Chemother Pharmacol. 2011; 68(5): 1263-1271.10.1007/s00280-011-1615-1', '[PubMed: 21442439]', '119', 'Beaver JA, Amiri-Kordestani L, Charlab R, et al. FDA approval: palbociclib for the treatment of', 'postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.', 'Clin Cancer Res. 2015;21(21):4760-4766.', '120', 'Dhillon S. Palbociclib: first global approval. Drugs. 2015;75(5):543-551.', '121', 'Yu Y, Loi CM, Hoffman J, Wang D. Physiologically Based Pharmacokinetic Modeling of', 'Palbociclib. J Clin Pharmacol. 2017 Feb;57(2):173-184. doi:10. 1.002/jcph.792. PubMed PMID:', '27402157.', '122', 'MusgroveEA Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin Das a therapeutic target', 'in cancer. Nat Rev Cancer. 2011 Jul 7;11(8):558-72. doi:10.1038/nrc3090. Review. PubMed', 'PMID: 21734724.', '123', 'Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell.', '2008 Feb; 14(2):159-69. doi: 10.1016/j.devcel.2008.01.013. Review. PubMed PMID: 18267085.', '124', 'Sherr CJ. ANew Cell-Cycle Target in Cancer - Inhibiting Cyclin D-Dependent Kinases 4 and 6. N', 'Engl J Med. 2016 Nov 17;375(20):1920-1923. PubMed PMID :27959598.', '83', 'NCI Version Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}